AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00520845 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed disodium
Description: 500 mg/m2 through a vein over 90 minutes on day 1 of a 3 week cycle.
Study NCT00520845 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Blood collection
Study NCT02751047 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: manual ventilation
Description: Facemask ventilation is performed by manual bagging with reservoir bag.
Study NCT02751047 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pressure controlled mechanical ventilation
Description: Facemask ventilation is performed with mechanical ventilator by pressure controlled mode.
Study NCT00387959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Study NCT00387959 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Study NCT00387959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00387959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00387959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00387959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Study NCT00387959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: allogeneic hematopoietic stem cell transplantation
Study NCT00387959 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: umbilical cord blood transplantation
Study NCT00387959 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: total-body irradiation
Study NCT01015677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6913
Study NCT01015677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 17-β estradiol
Study NCT01015677 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to MK-6913
Study NCT01015677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to MK-6913
Study NCT01015677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to 17-β estradiol
Study NCT01015677 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to 17-β estradiol
Study NCT01015677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-6913 25 mg
Study NCT01580904 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention: Pharmaceutical Care
Description: Patients will be followed by the pharmacist by the Pharmaceutical Care Practice
Study NCT02603692 — intervention group
Intervention type: OTHER
Intervention: PROMIS-QOL
Description: PROMIS questionnaires completed every 3 months for up to 2 years.
Study NCT01732549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasquinimod
Description: A patient's dose will escalate from one level to the next, once tolerability of the current dose is established. If tolerability issues arise at 0.5 or 1 mg/day, patients will have their dose reduced to 0.25 or 0.5 mg/day, respectively.
Study NCT01732549 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules are identical to tasquinimod capsules in appearance and excipients but exclude the active compound (tasquinimod), to be taken orally once a day with water and food
Study NCT03432468 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Valsartan 1
Description: the high dose of valsartan
Study NCT03432468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 1
Description: the high dose of valsartan
Study NCT03432468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Valsartan 80 mg
Description: a single dose of valsartan
Study NCT04231045 — intervention group
Intervention type: DEVICE
Intervention: PiCCO device cardiac monitoring
Description: PiCCO is a cardiac output monitor that combines pulse contour analysis and transpulmonary thermodilution technique.Haemodynamic monitoring~especially if complex mixed forms of shock (e.g. septic and cardiogenic) PAC unavailable or contra-indicated
Study NCT02232399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
Study NCT02232399 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Milrinone
Description: The drug infusion will be started after initiation of cardiopulmonary bypass and will continue for 24 hours.
Study NCT01660256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-12759
Description: Instillation, 4 times/day for 4 weeks
Study NCT01660256 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OPC-12759
Description: Instillation, 4 times/day for 4 weeks
Study NCT01660256 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02885662 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-3150
Description: CS-3150 2.5 to 5.0 mg , orally.
Study NCT02691988 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ICS withdrawal
Description: Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG) and inhaled corticosteroids are withdrawn.
Study NCT02691988 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Bronchodilator therapy is optimized according to the latest COPD guideline of the Dutch College of General Practitioners (NHG)
Study NCT02388152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF20513, low dose
Study NCT02388152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF20513, medium dose
Study NCT02388152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF20513, high dose
Study NCT02388152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lu AF20513, double high dose
Study NCT03343093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Restore Rehabilitation Program
Description: Multi-component, structured, biopsychosocial, online interactive program to address the sexual and urinary effects of prostate cancer treatment
Study NCT03343093 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: usual care, surveys every 3 months
Study NCT01371422 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Paravertebral Block (PVB)
Description: The T10, T11 and T12 paravertebral spaces on the operative side will be identified with ultrasound in all patients (Sonosite MicroMax, 2-5 MHz curvilinear probe).~In the PVB group, a 90mm 22g Tuohy needle will be inserted in-plane with the live ultrasound image over the transverse process at each of these levels and 5 mL of 0.5% ropivacaine will be injected at each level.
Study NCT01371422 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Ultrasonography and local infiltration of saline will only be performed
Study NCT01790295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Pre- Hematopoietic cell transplantation (HCT)
Description: Ruxolitinib (INC424) tablets will be started 60 days (day -65) prior to start of conditioning chemotherapy. The starting dose of Ruxolitinib will be determined according to baseline platelet count and will be modified according to platelet count at follow-up. The drug will be given in the maximum tolerated dose as defined in the protocol for 56 days, followed by 4 days of taper, and will be stopped completely at the planned start of conditioning therapy (starting on day -5) i.e. 5 days prior to stem cell infusion. The drug will be supplied as 5 mg tablets.
Study NCT01139359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darinaparsin
Description: I.V. darinaparsin given in a dose escalation manner, once a day for 5 days per cycle.
Study NCT01139359 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP
Description: Cyclophosphamide 750 mg/m2 IV Day 8 of each Cycle; Doxorubicin 50 mg/m2 IV Day 8 of each Cycle; Vincristine 1.4 mg/m2 IV Day 8 of each Cycle; Prednisone 100 mg oral Days 8-12 of each Cycle.
Study NCT01199068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-7017
Description: CS-7017 from 0.25 mg to 0.50 mg twice daily
Study NCT01199068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erlotinib
Description: Erlotinib 150 mg once daily
Study NCT03453047 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: S100β and Neuron specific enolase (NSE)
Description: S100β is 10.4 kDa protein. Synthesized with end feet processes of astrocytes in the brain S100β belongs to low molecular weight EF-hand type acidic calcium binding protein superfamily. This protein is metabolized in the kidneys and removed with urine. It is shown that S100β does not show differences due to ethnical groups or genders and is not affected by circadian rhythm. Although S100β is also found in other tissues, it is in higher concentrations in the brain so it can be used as an early indicator for brain damage.NSE is an SSS protein which exists in neurons and neuroendocrine tissues. NSE plays a role in glycolytic route in neurons as intracytoplasmic enzyme increasing serum level in case of neuron damage. Whilst S100β is the marker of astroglia dysfunction, NSE is the marker of neuronal dysfunction.
Study NCT02719288 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CLARIX® CORD 1K graft
Study NCT02264119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefradafiban tablet
Study NCT02264119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lefradafiban tablet
Study NCT02264119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole tablet
Study NCT02264119 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lefradafiban double chamber sachet
Study NCT02264119 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lefradafiban double chamber sachet
Study NCT03444402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381(formulation I)
Description: 1 tablet administered before the breakfast during 7 days
Study NCT03444402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CKD-381(formulation II)
Description: 1 tablet administered before the breakfast during 7 days
Study NCT03444402 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D026(Nexium 40mg)
Description: 1 tablet administered before the breakfast during 7 days
Study NCT04589299 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Immunoglobulin
Description: Randomization 1:1 to the same total dose of either SCIG or IVIG for 26 weeks of stable dose + 60 weeks of redcution.
Study NCT02876848 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OPTIMUM e-health tool
Description: If you are treated in a hospital that is using the OPTIMUM e-health tool (intervention group), once your care team receives any alerts, they may choose to:~* Contact you over the phone or in person to provide medical advice on how to better take your pills,~* Contact your pharmacist(s) and other doctors about your anti-cancer treatment.
Study NCT06331104 — intervention group
Intervention type: GENETIC
Intervention: gene expression levels
Description: 12 immunohistochemical sections were scored under the microscope (staining intensity scores: negative 0 points, weak 1 point, medium 2 points, strong 3 points; positive cell frequency scores: less than 5% 0 points, 2-25% 1 point, 26-50% 2 points, 51-75% 3 points, greater than 75% 4 points).
Study NCT01632189 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Varenicline will be administered as prescribed: 0.5 mg for the first 3 days then 1 mg for the next 7 days and 2 mg after that. A quit date will be chosen at 11 days after starting Varenicline. Varenicline will be given for 3 months.
Study NCT04345380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of an Alcon Acrysof SN60WF intraocular lens
Description: Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
Study NCT04345380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of an AMO Tecnis ZCB00 intraocular lens
Description: Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
Study NCT04345380 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Implantation of an Envista MX60 intraocular lens
Description: Patients suffering from senile cataract getting replaced their human crystalline cataractous lens
Study NCT04411134 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: E7 TCR
Description: Approximately 3x10\^8 or 1.5x10\^9 E7 TCR T cells will be injected on day 0 and 1.5x10\^9 E7 TCR T cells on day 31 (2 escalating dose levels)
Study NCT01198483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Micro- Surgery
Description: Microincision Cataract Surgery combined with 23-gauge/25-gauge/27 gauge Vitrectomy
Study NCT01198483 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Combined Small-Surgery
Description: Smallincision cataract surgery combined with 23 gauge vitrectomy
Study NCT01888250 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamotrigine
Description: Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
Study NCT01888250 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine Extended Release Tablets, 25mg, 50mg, 100mg, 200mg and 300 mg
Study NCT04423562 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT03894475 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AioCare
Description: AioCare is an ultraportable, handheld hardware module that contains the MEMS-based flow sensor and electronics, with a dedicated mobile application that works on iOS and Android operating systems. The unit is used with a disposable mouthpiece fitted to the tip of the flow tube, and a nose clip. AioCare is connected to its dedicated mobile application, which contains software that will show flow-volume graphs and results in real time. The device encompasses all of the widely used spirometry parameters, including: peak expiratory flow (PEF), forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC), FEV1/FVC ratio, forced expiratory flow at 25% of expiration (FEF25), forced expiratory flow at 50% of expiration (FEF50), forced expiratory flow at 75% of expiration (FEF75), and forced expiratory volume in 6 second (FEV6).
Study NCT03894475 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spirometer USB CPFS/D (MGC Diagnostics)
Description: Spirometer USB CPFS/D (MGC Diagnostics) is a diagnostic desktop spirometer used in hospitals/clinics. CPFS/D USB spirometer is compatible with desktop and laptop computers.
Study NCT00460746 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC125, Darunavir; Ritonavir
Description: TMC125-200mg two times a day for 48 weeks; Darunavir -200mg two times a day for 48 weeks; Ritonavir-100mg two times a day for 48 weeks;
Study NCT01597492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab plus Early Vaccination
Description: Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 28, 42, 56, and every 28 days thereafter through Week 32 (9 doses). Pneumococcal vaccination is administered 4 weeks prior to the first dose of belimumab.
Study NCT01597492 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Belimumab plus Late Vaccination
Description: Belimumab 10 mg/kg IV plus standard therapy for SLE is administered on Days 0, 14, 28, and then every 28 days thereafter through Week 28 (9 doses). Pneumococcal vaccination is administered 24 weeks after the first dose of belimumab.
Study NCT04350879 — intervention group
Intervention type: OTHER
Intervention: Data record
Description: Data record
Study NCT03518502 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transarterial chemoembolization (TACE)
Description: Standard therapy for intermediate HCC, but nor for advanced HCC
Study NCT03518502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Standard therapy for advanced HCC
Study NCT03518502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Standard therapy for advanced HCC
Study NCT00702026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: multispecies probiotic (Ecologic 801)
Description: once daily, 5 gram \[10e9 cfu/gram\]
Study NCT00702026 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: once daily, 5 gram \[10e9 cfu/gram\]
Study NCT02247297 — intervention group
Intervention type: PROCEDURE
Intervention: Blood collection
Description: Diagnostic blood collection
Study NCT02265939 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NPO-13
Study NCT02265939 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NPO-13
Study NCT00799799 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NK cells
Description: NK cells infusion after immunosuppressive chemotherapy
Study NCT02518815 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3M Bair Paws Warming System
Description: 20 minutes of prewarming immediately pre-operatively using 3M Bair Paws warming system
Study NCT01256580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab (Avastin; Genentech, Inc.)
Description: 1.25 mg bevacizumab (Avastin; Genentech, Inc.) by intravitreal injection
Study NCT01256580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab, Dexamethasone, Verteporfin Photodynamic Therapy
Description: Intravitreal injection of 1.25 mg bevacizumab (Avastin; Genentech, Inc.) combined with reduced-fluence verteporfin PDT (Visudyne®; Novartis) and 200ug of intravitreal dexamethasone
Study NCT02312206 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NEOD001
Description: NEOD001, is a humanized immunoglobulin G1 monoclonal antibody, which specifically targets misfolded light chain aggregates and amyloid deposits. NEOD001 is proposed for use to target the misfolded light chain protein in subjects with AL amyloidosis.
Study NCT02312206 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT01008163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-351/Placebo
Description: comparison of different dosages of drug
Study NCT01008163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: YY-351
Description: comparison of different dosages of drug
Study NCT01008163 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: comparison of different dosages of drug
Study NCT03672175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAGE-217
Description: SAGE-217 hard gelatin capsules.
Study NCT03672175 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: SAGE-217 matched placebo hard gelatin capsules.
Study NCT02818998 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, VEGF Trap-Eye, BAY86-5321)
Study NCT02444468 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flowtron ACS800
Description: Flowtron ACS800 and bandage
Study NCT02444468 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bandage
Description: Bandage only
Study NCT02444468 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bandage
Description: Bandage only
Study NCT04570696 — intervention group
Intervention type: OTHER
Intervention: NON INTERVENTIONAL
Description: NON INTERVENTIONAL
Study NCT00905034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: 200 mg/m\^2 by vein on days 1 and 15.
Study NCT00905034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.4 mg/m\^2 by vein (maximum dose 2 mg) on days 1, 8 and 15.
Study NCT00905034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-l-asparaginase
Description: 2500 International units/m\^2 by vein on days 2 and 16
Study NCT00905034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg by vein or by mouth daily days 1-4 and 15-18.
Study NCT00905034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab 375 mg/m\^2 by vein on days 1 and 15 (first 4 cycles) for patients CD20 positive or positive by immunostain.
Study NCT01938313 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERAS perioperative cares
Description: 1. Patient's preoperative counseling \& education before surgery~2. No Bowel preparation~3. Oral Carbohydrate Solution (OCS) loading until 2hours before surgery~4. Fluid restriction \& Management by pulse contour analysis or transesophageal doppler~5. Early mobilization~6. Early oral feeding (postoperative 1 day - sips of water, 2 days - semifluid diet (SFD), 3 days - soft blended diet (SBD))~7. Epidural patient controlled analgesics (no opioids analgesics)~8. Postoperative Nausea Active Control~9. Thromboembolism prophylaxis by low molecular weighted heparin (LMWH)~10. Perioperative High content Oxygen therapy~11. No drain insertion~12. No Levin tube~13. Patients will be discharged at POD#4 if there's no problem.